Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...

Sanofi's acquisition of Dynavax, valued at $2.2 billion, aims to enhance its vaccine portfolio, including a promising shingles vaccine candidate, Z-1018. Z-1018 has demonstrated comparable ...

WASHINGTON — The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients — revving up their immune systems to help fight tumors. People with advanced lung or skin ...

Novavax, the Covid-19 vaccine maker, has licensed the rights for a vaccine-enhancing component to Pfizer. Pfizer agreed to pay $30 million upfront, and could pay up to $500 million more if development ...

TAMPA, Fla. — Florida’s Department of Health is meeting in Panama City Beach on Friday to discuss potential changes to the state’s vaccine requirements, a proposal that could significantly alter which ...